Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

NCT03266783 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2760

Enrollment

OTHER

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Apixaban
DRUG: Rivaroxaban

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]